HALO - Bristol Myers' Lead Cancer Drug Opdivo Formulated As Under Skin Injection At Par With Intravenous Infusion In Kidney Cancer Patients | Benzinga
Saturday, Bristol Myers Squibb & Co (NYSE:BMY) released the first disclosure of data from the Phase 3 CheckMate -67T trial of the subcutaneous formulation of Opdivo (nivolumab) compared to intravenous (IV) Opdivo in advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy.
The subcutaneous Opdivo is co-formulated with Halozyme Therapeutics Inc’s (NASDAQ:HALO) recombinant human hyaluronidase.
Also Read: Bristol Myers, Exelixis Reveal 4-Year Followup Results From ...